| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Progesterone (micronised) |
| Brand | Utrogestan® |
| Indication | Progesterone (micronised) is indicated in women for supplementation of the luteal phase during ART cycles. |
| Assessment Process | |
| Rapid review commissioned | 14/10/2019 |
| Rapid review completed | 20/11/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that progesterone (micronised) be considered for reimbursement.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.